IDRA - Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc. (IDRA) is a clinical-stage biopharmaceutical company that develops and commercializes novel nucleic acid-based drug candidates for the treatment of cancer and rare diseases. The company's product candidates use its proprietary Toll-like receptor (TLR) technology to activate the immune system and induce an anti-tumor response.

As of its last market close, IDRA had a market capitalization of approximately $363 million USD. The company had a trailing twelve-month revenue of approximately $1.6 million USD and a net loss of approximately $69 million USD. IDRA's stock price had a 52-week range of $0.70 - $5.02 USD and was trading at approximately $1.25 USD at the time of its last market close.

Idera Pharmaceuticals is focused on advancing its product candidates through clinical trials and obtaining regulatory approval for commercialization. The company is also exploring partnerships and collaborations to expand the development and commercialization of its pipeline.

Investing in IDRA carries risks, including risks associated with the clinical development and regulatory approval process, as well as risks associated with competition and market conditions. Additionally, Idera Pharmaceuticals is subject to regulatory and geopolitical risks, including risks associated with changes in political and economic conditions in the countries where it operates. Investors should carefully consider these risks before making any investment decisions.

Stock Sector: Drugs: Biotechnology